Dr. Agarwal's Health Care profit and loss

Latest FY26

Revenue: ₹2,080cr+21.6% on FY25
EBITDA: ₹570cr+24.8% on FY25
Net profit: ₹168cr+52.4% on FY25
EPS: ₹4.21+50.4% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	2,207	2,080	1,711
	37.5	44.4	46.0
	2,244	2,125	1,757
	1.0	0.9	1.2
	218	202	174
	−14.4	−10.5	−12.8
	429	404	327
	89.1	90.5	109
	292	276	231
	961	914	766
	1,975	1,877	1,594
	612	570	456
	321	293	226
Profit
	269	247	163
	1.3	1.3	−3.0
	270	249	160
	88.4	81.0	39.3
	−3.3	−0.5	10.3
	85.1	80.5	49.5
	185	168	110
	185	168	110
	13.1	17.6	−0.5
	198	186	110
	148	133	83.5
	36.7	35.0	26.9
Per share
	₹4.69	₹4.21	₹2.80
	₹4.65	₹4.18	₹2.78
Other comprehensive income — detail
	13.1	17.6	−0.5
	−2.2	−0.7	−0.5
	−0.6	−0.2	−0.1
	—	18.1	−0.1
	−3.9	0.0	0.0
	162	151	82.9
	36.5	35.0	26.9
Per share — as-filed variants
	₹4.69	₹4.21	₹2.80
	₹4.65	₹4.18	₹2.78
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,002	1,887	1,549
	90.7%	90.7%	90.5%
Adjusted (ex-exceptional items) — derived
	269	247	163
	1.3	1.3	−3.0
	184	167	112
	₹4.67	₹4.19	₹2.85

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

AGARWALEYE₹488.70

Dr. Agarwal's Health Care Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersAKUMS ADVENZYMES ALIVUS AARTIPHARM AARTIDRUGS APLLTD CORONA HCGMcap ₹15,482 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	1,711.0	2,080.1	2,206.7
Other Income	46.0	44.4	37.5
Total Income	1,757.0	2,124.5	2,244.1
Expenses
+ Cost of Materials Consumed	1.2	0.9	1.0
+ Purchases of Stock-in-Trade	173.7	202.4	217.7
+ Changes in Inventories	-12.8	-10.5	-14.4
+ Employee Benefit Expense	326.9	403.8	429.3
+ Finance Costs	108.8	90.5	89.1
+ Depreciation & Amortisation	230.7	276.2	291.6
+ Other Expenses	765.7	913.9	960.9
Total Expenses	1,594.2	1,877.2	1,975.3
EBITDA	456.4	569.6	612.1
EBIT	225.6	293.3	320.5
Profit
PBT before Exceptional Items	162.9	247.3	268.9
+ Exceptional Items	-3.0	1.3	1.3
Pretax Income	159.9	248.6	270.2
+ Current Tax	39.3	81.0	88.4
+ Deferred Tax	10.3	-0.5	-3.3
Tax Expense	49.5	80.5	85.1
Net Income	110.3	168.1	185.1
+ Net Income — Continuing Ops	110.3	168.1	185.1
+ Other Comprehensive Income	-0.5	17.6	13.1
Total Comprehensive Income	109.8	185.7	198.2
Net Income to Common	83.5	133.2	148.4
Minority Interest	26.9	35.0	36.7
Per Share
Basic EPS	2.80	4.21	4.69
Diluted EPS	2.78	4.18	4.65
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.5	17.6	13.1
+ Items NOT to be Reclassified to P&L	-0.5	-0.7	-2.2
+ Tax on Items NOT to be Reclassified	-0.1	-0.2	-0.6
+ Items to be Reclassified to P&L	-0.1	18.1	—
+ Tax on Items to be Reclassified	0.0	0.0	-3.9
Comprehensive Income — Owners of Parent	82.9	150.8	161.7
Comprehensive Income — Non-controlling Interests	26.9	35.0	36.5
Per Share — as-filed variants
Basic EPS — Continuing Operations	2.80	4.21	4.69
Diluted EPS — Continuing Operations	2.78	4.18	4.65
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,548.9	1,887.3	2,002.4
Gross Margin %	90.53	90.73	90.74
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	162.9	247.3	268.9
− Exceptional Items (reconciliation)	-3.0	1.3	1.3
Net Income Adj (tax-effected)	112.4	167.2	184.2
EPS Adj	2.85	4.19	4.67
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	1.00	1.00	1.00
Paid Up Equity Capital	31.6	31.7	31.7

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.